Fulcrum Therapeutics (FULC) Cash & Equivalents (2018 - 2026)

Fulcrum Therapeutics (FULC) has reported Cash & Equivalents for 9 consecutive years, with $318.8 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Cash & Equivalents rose 648.66% year-over-year to $318.8 million; the TTM figure through Jun 2026 stood at $318.8 million (up 648.66% YoY), while the FY2025 annual figure was $352.3 million, up 46.17% from the prior year.
• Cash & Equivalents declined to $318.8 million in Q2 2026 per FULC's latest filing, from $333.3 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $352.3 million in Q4 2025 and bottomed at $30.1 million in Q3 2023.
• Historically, Cash & Equivalents has averaged $125.8 million across 5 years, with a median of $57.6 million in 2024.
• Annual changes were most pronounced in 2022 — Cash & Equivalents sank 66.93% — and 2026, when it jumped 690.26%.
• Fulcrum Therapeutics' Cash & Equivalents stood at $35.1 million in 2022, then jumped by 573.03% to $236.2 million in 2023, then advanced by 2.03% to $241.0 million in 2024, then soared by 46.17% to $352.3 million in 2025, then fell by 9.5% to $318.8 million in 2026.
• Business Quant data shows FULC's Cash & Equivalents at $318.8 million in Q2 2026, $333.3 million in Q1 2026, and $352.3 million in Q4 2025.